Swiss biotechnology company Roche Group (SIX: RO, ROG) (OTCQX: RHHBY) announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Roche Digital Pathology Dx (VENTANA DP 200) system.

This enables pathologists to use digital slide images for primary diagnosis, improving healthcare efficiency and patient care, particularly in areas with limited access to specialists.

The system is designed to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.

FDA clearance marks a significant step towards routine clinical use of Roche's digital pathology solutions.